Search results
Search for "antineoplastic" in Full Text gives 23 result(s) in Beilstein Journal of Organic Chemistry.
Synthesis of ether lipids: natural compounds and analogues
- Marco Antônio G. B. Gomes,
- Alicia Bauduin,
- Chloé Le Roux,
- Romain Fouinneteau,
- Wilfried Berthe,
- Mathieu Berchel,
- Hélène Couthon and
- Paul-Alain Jaffrès
Beilstein J. Org. Chem. 2023, 19, 1299–1369, doi:10.3762/bjoc.19.96
Graphical Abstract
Figure 1: Chemical structure of some natural ether lipids (ELs).
Figure 2: Synthesis of lyso-PAF and PAF from 1-O-alkylglycerol [64].
Figure 3: Synthesis of lyso-PAF from 1,3-benzylideneglycerol 3.1 [69].
Figure 4: A) Synthesis of the two enantiomers of octadecylglycerol (4.6 and 4.10) from ᴅ-mannitol (4.1); B) s...
Figure 5: Four-step synthesis of PAF 5.6 from (S)-glycidol [73].
Figure 6: Synthesis of 1-O-alkylglycerol A) from solketal, B) from ᴅ- or ʟ-tartaric acid and the intermediate ...
Figure 7: Synthesis of EL building blocks starting from substituted glycidol 7.1a–c [82].
Figure 8: Synthesis of PAF 8.5 by using phosphoramidite 8.2 [86].
Figure 9: Synthesis of oleyl-PAF 9.7 from ʟ-serine [88].
Figure 10: Synthesis of racemic analogues of lyso-PAF 10.8 and PAF 10.9 featuring a phenyl group between the g...
Figure 11: Synthesis of racemic deoxy-lyso-PAF 11.7 and deoxy-PAF 11.8 [91].
Figure 12: Synthesis of racemic thio-PAF 12.8 [93].
Figure 13: Racemic synthesis of 13.6 to illustrate the modification of the glycerol backbone by adding a methy...
Figure 14: Racemic synthesis of 14.5 as an illustration of the introduction of methyl substituents on the glyc...
Figure 15: Synthesis of functionalized sn-2-acyl chains of PC-EL; A) Steglich esterification or acylation reac...
Figure 16: Synthesis of racemic mc-PAF (16.3), a carbamate analogue of PAF [102].
Figure 17: A) Synthesis of (R)-17.2 and (S)-17.6 starting from (S)-solketal (17.1); B) synthesis of N3-PAF (17...
Figure 18: Modification of the phosphocholine polar head to produce PAF analogues [81].
Figure 19: Racemic PAF analogues 19.3 and 19.5 characterized by the absence of the phosphate group [107].
Figure 20: Synthesis of PIP3-PAF (20.7) [108].
Figure 21: Large-scale synthesis of C18-edelfosine (21.8) [116].
Figure 22: Synthesis of C16-edelfosine (22.10) starting from isopropylidene-ʟ-glyceric acid methyl ester (22.1...
Figure 23: Phosphocholine moiety installation by the use of chlorophosphite 23.2 as key reagent [119].
Figure 24: Synthesis of rac-1-alkyl-2-O-methylglycerol (AMG) [120].
Figure 25: Synthesis of stereocontrolled 1-alkyl-2-O-methyl glycerol 25.9 (AMG) from dimethyl ᴅ-tartrate [81].
Figure 26: A) Racemic synthesis of thioether 26.4 [129,130], B) structure of sulfone analogue 26.5 [129].
Figure 27: Stereocontrolled synthesis of C18-edelfosine thioether analogue 27.8 [118].
Figure 28: Synthesis of thioether 28.4 that include a thiophosphate function [134].
Figure 29: Synthesis of ammonium thioether 29.4 and 29.6 [135].
Figure 30: Synthesis of the N-methylamino analogue of edelfosine 30.6 (BN52211) [138].
Figure 31: Synthesis of 1-desoxy analogues of edelfosine; A) with a saturated alkyl chain; B) synthesis of the...
Figure 32: Stereocontrolled synthesis of edelfosine analogue (S)-32.8 featuring a C18:1 lipid chain [142].
Figure 33: Synthesis of edelfosine analogues with modulation of the lipid chain; A) illustration with the synt...
Figure 34: Synthesis of phospholipid featuring a carbamate function to link the lipid chain to the glycerol un...
Figure 35: Synthesis of sesquiterpene conjugates of phospho glycero ether lipids [148].
Figure 36: Racemic synthesis of methyl-substituted glycerol analogues 36.7 and 36.10: A) synthesis of diether ...
Figure 37: Racemic synthesis of ilmofosine (37.6) [155,156].
Figure 38: A) Stereoselective synthesis of 38.5 via a stereoselective hydroboration reaction; B) synthesis of ...
Figure 39: Racemic synthesis of SRI62-834 (39.6) featuring a spiro-tetrahydrofurane heterocycle in position 2 ...
Figure 40: Racemic synthesis of edelfosine analogue 40.5 featuring an imidazole moiety in sn-2 position [160].
Figure 41: Racemic synthesis of fluorine-functionalized EL: A) Synthesis of 41.6 and B) synthesis of 41.8 [161-163].
Figure 42: A) Synthesis of the β-keto-ester 42.6 that also features a decyl linker between the phosphate and t...
Figure 43: Synthesis of phosphonate-based ether lipids; A) edelfosine phosphonate analogue 43.7 and B) thioeth...
Figure 44: Enantioselective synthesis of phosphonates 44.3 and 44.4 [171].
Figure 45: Racemic synthesis of phosphinate-based ether lipid 45.10 [172].
Figure 46: Racemic synthesis of edelfosine arsonium analogue 46.5 [173].
Figure 47: Synthesis of edelfosine dimethylammonium analogue 47.2 [118].
Figure 48: Synthesis of rac-C18-edelfosine methylammonium analogue 48.4 [176].
Figure 49: A) Synthesis of edelfosine N-methylpyrrolidinium analogue 49.2 or N-methylmorpholinium analogue 49.3...
Figure 50: A) Synthesis of edelfosine’s analogue 50.4 with a PE polar group; B) illustration of a pyridinium d...
Figure 51: A) Synthesis of 51.4 featuring a thiazolium cationic moiety; B) synthesis of thiazolium-based EL 51...
Figure 52: Synthesis of cationic ether lipids 52.3, 52.4 and 52.6 [135,183].
Figure 53: Synthesis of cationic carbamate ether lipid 53.5 [184].
Figure 54: Synthesis of cationic sulfonamide 54.5 [185].
Figure 55: Chemical structure of ONO-6240 (55.1) and SRI-63-119 (55.2).
Figure 56: Synthesis of non-ionic ether lipids 56.2–56.9 [188].
Figure 57: Synthesis of ether lipid conjugated to foscarnet 57.6 [189].
Figure 58: A) Synthesis of ether lipid conjugated to arabinofuranosylcytosine; B) synthesis of AZT conjugated ...
Figure 59: Synthesis of quercetin conjugate to edelfosine [191].
Figure 60: Synthesis of 60.8 (Glc-PAF) [194].
Figure 61: A) Synthesis of amino ether lipid 61.7 functionalized with a rhamnose unit and its amide analogue 6...
Figure 62: A) Synthesis of glucose ether lipid 62.4; B) structure of ether lipid 62.5 possessing a maltose uni...
Figure 63: A) Synthesis of glucuronic methyl ester 63.8; B) structure of cellobiose 63.9 and maltose 63.10 ana...
Figure 64: A) Synthesis of maltosyl glycerolipid 64.7; B) structure of lactose analogue 64.8 prepared followin...
Figure 65: A) Asymmetric synthesis of the aglycone moiety starting from allyl 4-methoxyphenyl ether; B) glycos...
Figure 66: A) Synthesis of ohmline possessing a lactose moiety. B) Structure of other glyco glycero lipids pre...
Figure 67: A) Synthesis of lactose-glycerol ether lipid 67.5; B) analogues possessing a maltose (67.6) or meli...
Figure 68: Synthesis of digalactosyl EL 68.6, A) by using trityl, benzyl and acetyl protecting groups, B) by u...
Figure 69: A) Synthesis of α-ohmline; B) structure of disaccharide ether lipids prepared by using similar meth...
Figure 70: Synthesis of lactose ether lipid 70.3 and its analogue 70.6 featuring a carbamate function as linke...
Figure 71: Synthesis of rhamnopyranoside diether 71.4 [196].
Figure 72: Synthesis of 1-O-hexadecyl-2-O-methyl-3-S-(α-ᴅ-1'-thioglucopyranosyl)-sn-glycerol (72.5) [225].
Figure 73: A) Preparation of lipid intermediate 73.4; B) synthesis of 2-desoxy-C-glycoside 73.10 [226].
Figure 74: Synthesis of galactose-pyridinium salt 74.3 [228].
Figure 75: Synthesis of myo-inositol derivative Ino-C2-PAF (75.10) [230].
Figure 76: A) Synthesis of myo-inositol phosphate building block 76.7; B) synthesis of myo-inositolphosphate d...
Figure 77: A) Synthesis of phosphatidyl-3-desoxy-inositol 77.4; B) synthesis of phosphono-3-desoxyinositol 77.9...
Figure 78: A) Structure of diether phosphatidyl-myo-inositol-3,4-diphosphate 78.1; B) synthesis of phosphatidy...
Figure 79: A) Synthesis of diether-phosphatidyl derivative 79.4 featuring a hydroxymethyl group in place of a ...
Figure 80: Synthesis of Glc-amine-PAF [78].
Figure 81: Synthesis of glucosamine ether lipid 81.4 and its analogues functionalized in position 3 of the ami...
Figure 82: Synthesis of fully deprotected aminoglucoside ether lipid 82.5 [246].
Figure 83: Synthesis of C-aminoglycoside 83.12 using Ramberg–Bäcklund rearrangement as a key step [250].
Figure 84: A) List of the most important glyco lipids and amino glyco lipids included in the study of Arthur a...
Figure 85: Synthesis of mannosamine ether lipid 85.6 [254].
Figure 86: A) Synthesis of glucosamine ether lipids with a non-natural ʟ-glucosamine moiety; B) synthesis of e...
Figure 87: A) Structure of the most efficient anticancer agents 87.1–87.4 featuring a diamino glyco ether lipi...
Figure 88: A) Synthesis of diamino glyco ether lipid 87.4; B) synthesis of bis-glycosylated ether lipid 88.10 [256]....
Figure 89: Synthesis of triamino ether lipid 89.4 [260].
Figure 90: Synthesis of chlorambucil conjugate 90.7 [261].
Figure 91: Three main methods for the preparation of glycerol ether lipid 91.3; A) from solketal and via a tri...
Figure 92: Four different methods for the installation of the phosphocholine polar head group; A) method using...
Figure 93: Illustration of two methods for the installation of saccharides or aminosaccharides; A) O-glycosyla...
Combretastatins D series and analogues: from isolation, synthetic challenges and biological activities
- Jorge de Lima Neto and
- Paulo Henrique Menezes
Beilstein J. Org. Chem. 2023, 19, 399–427, doi:10.3762/bjoc.19.31
- characterized as an oxa[1.7]meta-paracyclophane framework. In the literature we can find reports about the isolation/synthesis of combretastatins D and their analogues which showed different biological activities, e.g., antineoplastic, anti-inflammatory, and α-glucosidase inhibition [13][14][15]. The presence
Graphical Abstract
Figure 1: Structures of some members of the combretastatin D series, corniculatolides, and isocorniculatolide...
Scheme 1: Biosynthetic pathway proposed by Pettit and co-workers.
Scheme 2: Biosynthetic pathway towards corniculatolides or isocorniculatolides proposed by Ponnapalli and co-...
Scheme 3: Retrosynthetic approaches.
Scheme 4: Attempt of total synthesis of 2 by Boger and co-workers employing the Mitsunobu approach [27].
Scheme 5: Total synthesis of combretastatin D-2 (2) reported by Boger and co-workers employing an intramolecu...
Scheme 6: Formal synthesis of combretastatin D-2 (2) by Deshpande and co-workers using the Mitsunobu conditio...
Scheme 7: Total synthesis of combretastatin D-2 (2) by Rychnovsky and Hwang [36].
Scheme 8: Divergent synthesis of (±)-1 form combretastatin D-2 (2) by Rychnovsky and Hwang [36].
Scheme 9: Enantioselective synthesis of 1 by Rychnovsky and Hwang employing Jacobsen catalyst [41].
Scheme 10: Synthesis of fragment 57 by Couladouros and co-workers [43,45].
Scheme 11: Formal synthesis of compound 2 by Couladouros and co-workers [43,45].
Scheme 12: Synthesis of fragment 66 by Couladouros and co-workers [44,45].
Scheme 13: Synthesis of fragment 70 by Couladouros and co-workers [44,45].
Scheme 14: Synthesis of fragment 77 by Couladouros and co-workers [44,45].
Scheme 15: Synthesis of combretastatins 1 and 2 by Couladouros and co-workers [44,45].
Scheme 16: Formal synthesis of compound 2 by Gangakhedkar and co-workers [48].
Scheme 17: Synthesis of fragment 14 by Cousin and co-workers [50].
Scheme 18: Synthesis of fragment 91 by Cousin and co-workers [50].
Scheme 19: Formal synthesis of compound 2 by Cousin and co-workers [50].
Scheme 20: Synthesis of 2 diolide by Cousin and co-workers [50].
Scheme 21: Synthesis of combretastatin D-4 (4) by Nishiyama and co-workers [54].
Scheme 22: Synthesis of fragment 112 by Pettit and co-workers [55].
Scheme 23: Synthesis of fragment 114 by Pettit and co-workers [55].
Scheme 24: Attempt to the synthesis of compound 2 by Pettit and co-workers [55].
Scheme 25: Synthesis of combretastatin-D2 (2) starting from isovanilin (80) by Pettit and co-workers [55].
Scheme 26: Attempted synthesis of combretastatin-D2 (2) derivatives through an SNAr approach [55].
Scheme 27: Synthesis of combretastatin D-4 (4) by Pettit and co-workers [55].
Scheme 28: Synthesis of combretastatin D-2 (2) by Harras and co-workers [57].
Scheme 29: Synthesis of combretastatin D-4 (4) by Harras and co-workers [57].
Scheme 30: Formal synthesis of combretastatin D-1 (1) by Harras and co-workers [57].
Scheme 31: Synthesis of 11-O-methylcorniculatolide A (5) by Raut and co-workers [69].
Scheme 32: Synthesis of isocorniculatolide A (7) and O-methylated isocorniculatolide A 8 by Raut and co-worker...
Scheme 33: Synthesis of isocorniculatolide B (10) and hydroxyisocorniculatolide B 175 by Kim and co-workers [71].
Scheme 34: Synthesis of compound 9, 178, and 11 by Kim and co-workers [71].
Scheme 35: Synthesis of combretastatin D-2 prodrug salts [55].
Figure 2: ED50 values of the combretastatin D family against murine P388 lymphocytic leukemia cell line (appr...
Figure 3: IC50 of compounds against α-glucosidase [19].
Anion exchange resins in phosphate form as versatile carriers for the reactions catalyzed by nucleoside phosphorylases
- Julia N. Artsemyeva,
- Ekaterina A. Remeeva,
- Tatiana N. Buravskaya,
- Irina D. Konstantinova,
- Roman S. Esipov,
- Anatoly I. Miroshnikov,
- Natalia M. Litvinko and
- Igor A. Mikhailopulo
Beilstein J. Org. Chem. 2020, 16, 2607–2622, doi:10.3762/bjoc.16.212
- wearisome [5][66]. This evidence prompted us to engage in the design and development of an efficient biotechnological synthetic route. Cladribine has been known for over 30 years as antineoplastic (Leustatine®) and anti-multiple sclerosis agent (for a few leading references, see [67][68][69][70]). The
Graphical Abstract
Scheme 1: General scheme of the suggested synthesis of nucleosides employing the enzymatic phosphorolysis of ...
Figure 1: Phosphorolysis (5.0 mM K-phosphate buffer, pH 7.0; 23 °C) of Ara-U and thymidine (Thd) catalyzed by...
Scheme 2: Transarabinosylation of O6-methylguanine (OMG) employing Ara-U as a donor of the Ara-1Pi (1:1.5 mol...
Figure 2: Optimized conditions of phosphorolysis of Ara-U: 0.20 mmol of Ara-U in distilled water (30 mL) cont...
Scheme 3: Synthesis of nelarabine with intermediate preparation of crude Ara-1Pi.
Scheme 4: Synthesis of kinetin riboside with intermediate preparation of crude Rib-1Pi.
Isolation of fungi using the diffusion chamber device FIND technology
- Benjamin Libor,
- Henrik Harms,
- Stefan Kehraus,
- Ekaterina Egereva,
- Max Crüsemann and
- Gabriele M. König
Beilstein J. Org. Chem. 2019, 15, 2191–2203, doi:10.3762/bjoc.15.216
- antibiotics (e.g., cephalosporins), immunosuppressants (e.g., mycophenolic acid) and immunomodulators (e.g., fingolimod), as well as cholesterol lowering agents (statins). Generally, fungal metabolites were shown to have antiviral, cytotoxic, antineoplastic, cardiovascular, anti-inflammatory, immune
Graphical Abstract
Scheme 1: Design and functional parts of the FIND technology.
Scheme 2: Isolation of fungal strains with the FIND technology. 1. Collection of terrestrial or marine sample...
Figure 1: Secondary metabolites isolated from H. cf. alpina.
Figure 2: a) Significant 1H,1H-COSY and 1H,13C-HMBC correlations for compounds 1 and 2. b) Key NOESY correlat...
Comparative cell biological study of in vitro antitumor and antimetastatic activity on melanoma cells of GnRH-III-containing conjugates modified with short-chain fatty acids
- Eszter Lajkó,
- Sarah Spring,
- Rózsa Hegedüs,
- Beáta Biri-Kovács,
- Sven Ingebrandt,
- Gábor Mező and
- László Kőhidai
Beilstein J. Org. Chem. 2018, 14, 2495–2509, doi:10.3762/bjoc.14.226
- internalize into the cells by receptor-mediated manner, where the attached drug should be released from the conjugate in order to exert its antineoplastic activity [1]. The first GnRH-drug hybrids were developed by Schally and co-workers [9]. One of their most efficient conjugates was the zoptarelin
- able to deliver Dau to A2058 human melanoma cells and provide its antineoplastic activity. The presence of short-chain fatty acid containing Lys in position 4 was shown to be accompanied by an increased cellular uptake and a higher long-term cytotoxic activity mediated via a PI3K-dependent signaling
Graphical Abstract
Figure 1: Schematic structure of Dau-conjugated GnRH-III or its derivatives containing 4Lys with acetyl or bu...
Figure 2: Cellular uptake of Dau–GnRH-III conjugates and free daunorubicin (Dau) by A2058 cells. Cellular upt...
Figure 3: Short-term growth inhibitory effects of the conjugates and daunorubicin (Dau) on A2058 cells. The m...
Figure 4: Effects of conjugates and daunorubicin (Dau) on cell cycle progression of A2058 melanoma cells. The...
Figure 5: Effects of the conjugates and daunorubicin (Dau) on melanoma cell adhesion. The Delta CI (Delta Cel...
Figure 6: Chemotactic effects of Dau–GnRH-III conjugates on A2058 cell line. The ‘Chemotaxis index’ (Chtx. in...
Figure 7: Effects of GnRH-III(Dau=Aoa) (a–c), [4Lys(Ac)]-GnRH-III(Dau=Aoa) (d–f) and [4Lys(Bu)]-GnRH-III(Dau=...
Figure 8: Schematic representation of the proposed mechanisms of the effects of GnRH-III conjugates containin...
Anomeric modification of carbohydrates using the Mitsunobu reaction
- Julia Hain,
- Patrick Rollin,
- Werner Klaffke and
- Thisbe K. Lindhorst
Beilstein J. Org. Chem. 2018, 14, 1619–1636, doi:10.3762/bjoc.14.138
- addition, 4 was also converted with the phyllanthostatin aglycone 8 to give 10 with inversion of anomeric configuration. Extension of this work to other more complex antineoplastic glycosyl esters was successfully investigated by the same group [30][31][32][33][34]. De Mesmaeker et al. reported the
Graphical Abstract
Scheme 1: Left: The Mitsunobu reaction is essentially a nucleophilic substitution of alcohols occurring with ...
Scheme 2: Mechanistic considerations on the Mitsunobu reaction with carbohydrate hemiacetals (depicted in sim...
Scheme 3: Anomeric esterification using the Mitsunobu procedure [29].
Scheme 4: Conversion of allyl glucuronate into various 1-O-esterified allyl glucuronates using anomeric Mitsu...
Scheme 5: Synthesis of anomeric glycosyl esters as substrates for Au-catalyzed glycosylation [40].
Scheme 6: Correlation between pKa value of the employed acids (or alcohol) and the favoured anomeric configur...
Scheme 7: Synthesis of the β-mannosyl phosphates for the synthesis of HBP 43 by anomeric phosphorylation acco...
Scheme 8: Synthesis of phenyl glycosides 44 and 45 from unprotected sugars [24].
Scheme 9: Synthesis of azobenzene mannosides 47 and 48 without protecting group chemistry [46].
Scheme 10: Synthesis of various aryl sialosides using Mitsunobu glycosylation [25].
Scheme 11: Mitsunobu synthesis of different jadomycins [54,55]. BOM: benzyloxymethyl.
Scheme 12: Stereoselectivity in the Mitsunobu synthesis of catechol glycosides in the gluco- and manno-series [56]....
Scheme 13: Formation of a 1,2-cis glycoside 80 assisted by steric hindrance of the β-face of the disaccharide ...
Scheme 14: Stereoselective β-D-mannoside synthesis [60].
Scheme 15: TIPS-assisted synthesis of 1,2-cis arabinofuranosides [63]. TIPS: triisopropylsilyl.
Scheme 16: The Mitsunobu reaction with glycals leads to interesting rearrangement products [69].
Scheme 17: Synthesis of disaccharides using mercury(II) bromide as co-activator in the Mitsunobu reaction [75].
Scheme 18: Synthesis of various fructofuranosides according to Mitsunobu and proposed neighbouring group parti...
Scheme 19: The Mitsunobu reaction allows stereoslective acetalization of dihydroartemisinin [77].
Scheme 20: Synthesis of alkyl thioglycosides by Mitsunobu reaction [81].
Scheme 21: Preparation of iminoglycosylphthalimide 115 from 114 [85].
Scheme 22: Mitsunobu reaction as a key step in the total synthesis of aurantoside G [87].
Scheme 23: Utilization of an N–H acid in the Mitsunobu reaction [88].
Scheme 24: Mitsunobu reaction with 1H-tetrazole [89].
Scheme 25: Formation of a rebeccamycin analogue using the Mitsunobu reaction [101].
Scheme 26: Synthesis of carbohydrates with an alkoxyamine bond [114].
Scheme 27: Synthesis of glycosyl fluorides and glycosyl azides according to Mitsunobu [118,119].
Scheme 28: Anomeric oxidation under Mitsunobu conditions [122].
Glycosylation reactions mediated by hypervalent iodine: application to the synthesis of nucleosides and carbohydrates
- Yuichi Yoshimura,
- Hideaki Wakamatsu,
- Yoshihiro Natori,
- Yukako Saito and
- Noriaki Minakawa
Beilstein J. Org. Chem. 2018, 14, 1595–1618, doi:10.3762/bjoc.14.137
- . Design of potential antineoplastic nucleosides. Concept of the Pummerer-type glycosylation and hypervalent iodine-mediated glycosylation. Speculated mechanism of oxidative glycosylation mediated by hypervalent iodine. Concept of the oxidative coupling reaction applicable to the synthesis of carbocyclic
Graphical Abstract
Figure 1: Design of potential antineoplastic nucleosides.
Scheme 1: Synthesis of 4’-thioDMDC.
Scheme 2: Synthesis of 4’-thioribonucleosides by Minakawa and Matsuda.
Scheme 3: Synthesis of 4’-thioribonucleosides by Yoshimura.
Figure 2: Concept of the Pummerer-type glycosylation and hypervalent iodine-mediated glycosylation.
Scheme 4: Oxidative glycosylation of 4-thioribose mediated by hypervalent iodine.
Figure 3: Speculated mechanism of oxidative glycosylation mediated by hypervalent iodine.
Scheme 5: Synthesis of purine 4’-thioribonucleosides using hypervalent iodine-mediated glycosylation.
Scheme 6: Unexpected glycosylation of a thietanose derivative.
Scheme 7: Speculated mechanism of the ring expansion of a thietanose derivative.
Scheme 8: Synthesis of thietanonucleosides using the Pummerer-type glycosylation.
Scheme 9: First synthesis of 4’-selenonucleosides.
Scheme 10: The Pummerer-type glycosylation of 4-selenoxide 74.
Scheme 11: Synthesis of purine 4’-selenonucleosides using hypervalent iodine-mediated glycosylation.
Figure 4: Concept of the oxidative coupling reaction applicable to the synthesis of carbocyclic nucleosides.
Scheme 12: Oxidative coupling reaction mediated by hypervalent iodine.
Scheme 13: Synthesis of cyclohexenyl nucleosides using an oxidative coupling reaction.
Figure 5: Concept of the oxidative coupling reaction of glycal derivatives.
Scheme 14: Oxidative coupling reaction of silylated uracil and DHP using hypervalent iodine.
Scheme 15: Proposed mechanism of the oxidative coupling reaction mediated by hypervalent iodine.
Figure 6: Synthesis of 2’,3’-unsaturated nucleosides using hypervalent iodine and a co-catalyst.
Scheme 16: Synthesis of dihydropyranonucleoside.
Scheme 17: Synthesis of acetoxyacetals using hypervalent iodine and addition of silylated base.
Scheme 18: One-pot fragmentation-nucleophilic additions mediated by hypervalent iodine.
Figure 7: The reaction of thioglycoside with hypervalent iodine in the presence of Lewis acids.
Scheme 19: Synthesis of disaccharides employing thioglycosides under an oxidative coupling reaction mediated b...
Scheme 20: Synthesis of disaccharides using disarmed thioglycosides by hypervalent iodine-mediated glycosylati...
Scheme 21: Glycosylation using aryl(trifluoroethyl)iodium triflimide.
Figure 8: Expected mechanism of hypervalent iodine-mediated glycosylation with glycals.
Scheme 22: Synthesis of oligosaccharides by hypervalent iodine-mediated glycosylation with glycals.
Scheme 23: Synthesis of 2-deoxy amino acid glycosides.
Figure 9: Rationale for the intramolecular migration of the amino acid unit.
One hundred years of benzotropone chemistry
- Arif Dastan,
- Haydar Kilic and
- Nurullah Saracoglu
Beilstein J. Org. Chem. 2018, 14, 1120–1180, doi:10.3762/bjoc.14.98
- ][18][19][20][21][22][23] (isolated from the heartwood and essential oils of trees of the family Cupressaceae), to complex macrocyclic analogues, such as harringtonolide (5) [24][25][26], which was found to have antineoplastic and antiviral properties, and caulersin (6) [26], which is a biologically
Graphical Abstract
Scheme 1: Tropone (1), tropolone (2) and their resonance structures.
Figure 1: Natural products containing a tropone nucleus.
Figure 2: Possible isomers 11–13 of benzotropone.
Scheme 2: Synthesis of benzotropones 11 and 12.
Scheme 3: Oxidation products of benzotropylium fluoroborate (16).
Scheme 4: Oxidation of 7-bromo-5H-benzo[7]annulene (22).
Scheme 5: Synthesis of 4,5-benzotropone (11) using o-phthalaldehyde (27).
Scheme 6: Synthesis of 4,5-benzotropone (11) starting from oxobenzonorbornadiene 31.
Scheme 7: Acid-catalyzed cleavage of oxo-bridge of 34.
Scheme 8: Synthesis of 4,5-benzotropone (11) from o-xylylene dibromide (38).
Scheme 9: Synthesis of 4,5-benzotropone (11) via the carbene adduct 41.
Scheme 10: Heck coupling strategy for the synthesis of 11.
Scheme 11: Synthesis of benzofulvalenes via carbonyl group of 4,5-benzotropone (11).
Figure 3: Some cycloheptatrienylium cations.
Scheme 12: Synthesis of condensation product 63 and its subsequent oxidative cyclization products.
Figure 4: A novel series of benzo[7]annulenes prepared from 4,5-benzotropone (11).
Scheme 13: Preparation of substituted benzo[7]annulene 72 using the Mukaiyama-Michael reaction.
Figure 5: Possible benzo[7]annulenylidenes 73–75.
Scheme 14: Thermal and photochemical decomposition of 7-diazo-7H-benzo[7]annulene (76) and the trapping of int...
Scheme 15: Synthesis of benzoheptafulvalene 86.
Scheme 16: Synthesis of 7-(diphenylmethylene)-7H-benzo[7]annulene (89).
Scheme 17: Reaction of 4,5-benzotropone (11) with dimethyl diazomethane.
Scheme 18: Synthesis of dihydrobenzomethoxyazocine 103.
Scheme 19: Synthesis and reducibility of benzo-homo-2-methoxyazocines.
Scheme 20: Synthesis of 4,5-benzohomotropones 104 and 115 from 4,5-benzotropones 11 and 113.
Scheme 21: A catalytic deuterogenation of 4,5-benzotropone (11) and synthesis of 5-monosubstituted benzo[7]ann...
Scheme 22: Synthesis of methyl benzo[7]annulenes 131 and 132.
Scheme 23: Ambident reactivity of halobenzo[7]annulenylium cations 133a/b.
Scheme 24: Preparation of benzo[7]annulenylidene–iron complexes 147.
Scheme 25: Synthesis of 1-ethynylbenzotropone (150) and the etheric compound 152 from 4,5-benzotropone (11) wi...
Scheme 26: Thermal decomposition of 4,5-benzotropone (11).
Scheme 27: Reaction of 4,5-benzotropone (11) with 1,2-ethanediol and 1,2-ethanedithiol.
Scheme 28: Conversions of 1-benzosuberone (162) to 2,3-benzotropone (12).
Scheme 29: Synthesis strategies for 2,3-bezotropone (12) using 1-benzosuberones.
Scheme 30: Oxidation-based synthesis of 2,3-benzotropone (12) via 1-benzosuberone (162).
Scheme 31: Synthesis of 2,3-benzotropone (12) from α-tetralone (171) via ring-expansion.
Scheme 32: Preparation of 2,3-benzotropone (12) by using of benzotropolone 174.
Figure 6: Benzoheptafulvenes as condensation products of 2,3-benzotropone (12).
Scheme 33: Conversion of 2,3-benzotropone (12) to tosylhydrazone salt 182 and gem-dichloride 187.
Figure 7: Benzohomoazocines 191–193 and benzoazocines 194–197.
Scheme 34: From 2,3-benzotropone (12) to carbonium ions 198–201.
Scheme 35: Cycloaddition reactions of 2,3-benzotropone (12).
Scheme 36: Reaction of 2,3-benzotropone (12) with various reagents and compounds.
Figure 8: 3,4-Benzotropone (13) and its resonance structure.
Scheme 37: Synthesis of 6,7-benzobicyclo[3.2.0]hepta-3,6-dien-2-one (230).
Figure 9: Photolysis and thermolysis products of 230.
Figure 10: Benzotropolones and their tautomeric structures.
Scheme 38: Synthesis strategies of 4,5-benzotropolone (238).
Scheme 39: Synthesis protocol for 2-hydroxy-4,5-benzotropone (238) using oxazole-benzo[7]annulene 247.
Figure 11: Some quinoxaline and pyrazine derivatives 254–256 prepared from 4,5-benzotropolone (238).
Scheme 40: Nitration product of 4,5-benzotropolone (238) and its isomerization to 1-nitro-naphthoic acid (259)....
Scheme 41: Synthesis protocol for 6-hydroxy-2,3-benzotropone (239) from benzosuberone (162).
Scheme 42: Various reactions via 6-hydroxy-2,3-benzotropone (239).
Scheme 43: Photoreaction of 6-hydroxy-2,3-benzotropone (239).
Scheme 44: Synthesis of 7-hydroxy-2,3-benzotropone (241) from benzosuberone (162).
Scheme 45: Synthesis strategy for 7-hydroxy-2,3-benzotropone (241) from ketone 276.
Scheme 46: Synthesis of 7-hydroxy-2,3-benzotropone (241) from β-naphthoquinone (280).
Scheme 47: Synthesis of 7-hydroxy-2,3-benzotropone (241) from bicyclic endoperoxide 213.
Scheme 48: Synthesis of 7-hydroxy-2,3-benzotropone (241) by ring-closing metathesis.
Figure 12: Various monosubstitution products 289–291 of 7-hydroxy-2,3-benzotropone (241).
Scheme 49: Reaction of 7-hydroxy-2,3-benzotropone (241) with various reagents.
Scheme 50: Synthesis of 4-hydroxy-2,3-benzotropones 174 and 304 from diketones 300/301.
Scheme 51: Catalytic hydrogenation of diketones 300 and 174.
Scheme 52: Synthesis of halo-benzotropones from alkoxy-naphthalenes 306, 307 and 310.
Figure 13: Unexpected byproducts 313–315 during synthesis of chlorobenzotropone 309.
Figure 14: Some halobenzotropones and their cycloadducts.
Scheme 53: Multisep synthesis of 2-chlorobenzotropone 309.
Scheme 54: A multistep synthesis of 2-bromo-benzotropone 26.
Scheme 55: A multistep synthesis of bromo-2,3-benzotropones 311 and 316.
Scheme 56: Oxidation reactions of 8-bromo-5H-benzo[7]annulene (329) with some oxidants.
Scheme 57: Synthesis of 2-bromo-4,5-benzotropone (26).
Scheme 58: Synthesis of 6-chloro-2,3-benzotropone (335) using LiCl and proposed intermediate 336.
Scheme 59: Reaction of 7-bromo-2,3-benzotropone (316) with methylamine.
Scheme 60: Reactions of bromo-2,3-benzotropones 26 and 311 with dimethylamine.
Scheme 61: Reactions of bromobenzotropones 311 and 26 with NaOMe.
Scheme 62: Reactions of bromobenzotropones 26 and 312 with t-BuOK in the presence of DPIBF.
Scheme 63: Cobalt-catalyzed reductive cross-couplings of 7-bromo-2,3-benzotropone (316) with cyclic α-bromo en...
Figure 15: Cycloadduct 357 and its di-π-methane rearrangement product 358.
Scheme 64: Catalytic hydrogenation of 2-chloro-4,5-benzotropone (311).
Scheme 65: Synthesis of dibromo-benzotropones from benzotropones.
Scheme 66: Bromination/dehydrobromination of benzosuberone (162).
Scheme 67: Some transformations of isomeric dibromo-benzotropones 261A/B.
Scheme 68: Transformations of benzotropolone 239B to halobenzotropolones 369–371.
Figure 16: Bromobenzotropolones 372–376 and 290 prepared via bromination/dehydrobromination strategy.
Scheme 69: Synthesis of some halobenzotropolones 289, 377 and 378.
Figure 17: Bromo-chloro-derivatives 379–381 prepared via chlorination.
Scheme 70: Synthesis of 7-iodo-3,4-benzotropolone (382).
Scheme 71: Hydrogenation of bromobenzotropolones 369 and 370.
Scheme 72: Debromination reactions of mono- and dibromides 290 and 375.
Figure 18: Nitratation and oxidation products of some halobenzotropolenes.
Scheme 73: Azo-coupling reactions of some halobenzotropolones 294, 375 and 378.
Figure 19: Four possible isomers of dibenzotropones 396–399.
Figure 20: Resonance structures of tribenzotropone (400).
Scheme 74: Two synthetic pathways for tribenzotropone (400).
Scheme 75: Synthesis of tribenzotropone (400) from dibenzotropone 399.
Scheme 76: Synthesis of tribenzotropone (400) from 9,10-phenanthraquinone (406).
Scheme 77: Synthesis of tribenzotropone (400) from trifluoromethyl-substituted arene 411.
Figure 21: Dibenzosuberone (414).
Figure 22: Reduction products 415 and 416 of tribenzotropone (400).
Figure 23: Structures of tribenzotropone dimethyl ketal 417 and 4-phenylfluorenone (412) and proposed intermed...
Figure 24: Structures of benzylidene- and methylene-9H-tribenzo[a,c,e][7]annulenes 419 and 420 and chiral phos...
Figure 25: Structures of tetracyclic alcohol 422, p-quinone methide 423 and cation 424.
Figure 26: Structures of host molecules 425–427.
Scheme 78: Synthesis of non-helical overcrowded derivatives syn/anti-431.
Figure 27: Hexabenzooctalene 432.
Figure 28: Structures of possible eight isomers 433–440 of naphthotropone.
Scheme 79: Synthesis of naphthotropone 437 starting from 1-phenylcycloheptene (441).
Scheme 80: Synthesis of 10-hydroxy-11H-cyclohepta[a]naphthalen-11-one (448) from diester 445.
Scheme 81: Synthesis of naphthotropone 433.
Scheme 82: Synthesis of naphthotropones 433 and 434 via cycloaddition reaction.
Scheme 83: Synthesis of naphthotropone 434 starting from 452.
Figure 29: Structures of tricarbonyl(tropone)irons 458, and possible cycloadducts 459.
Scheme 84: Synthesis of naphthotropone 436.
Scheme 85: Synthesis of precursor 465 for naphthotropone 435.
Scheme 86: Generation of naphthotropone 435 from 465.
Figure 30: Structures of tropylium cations 469 and 470.
Figure 31: Structures of tropylium ions 471+.BF4−, 472+.BF4−, and 473+.BF4−.
Scheme 87: Synthesis of tropylium ions 471+.BF4− and 479+.ClO4−.
Scheme 88: Synthesis of 1- and 2-methylanthracene (481 and 482) via carbene–carbene rearrangement.
Figure 32: Trapping products 488–490.
Scheme 89: Generation and chemistry of a naphthoannelated cycloheptatrienylidene-cycloheptatetraene intermedia...
Scheme 90: Proposed intermediates and reaction pathways for adduct 498.
Scheme 91: Exited-state intramolecular proton transfer of 505.
Figure 33: Benzoditropones 506 and 507.
Scheme 92: Synthesis of benzoditropone 506e.
Scheme 93: Synthetic approaches for dibenzotropone 507 via tropone (1).
Scheme 94: Formation mechanisms of benzoditropone 507 and 516 via 515.
Scheme 95: Synthesis of benzoditropones 525 and 526 from pyromellitic dianhydride (527).
Figure 34: Possible three benzocyclobutatropones 534–536.
Scheme 96: Synthesis of benzocyclobutatropones 534 and 539.
Scheme 97: Synthesis attempts for benzocyclobutatropone 545.
Scheme 98: Generation and trapping of symmetric benzocyclobutatropone 536.
Scheme 99: Synthesis of chloro-benzocyclobutatropone 552 and proposed mechanism of fluorenone derivatives.
Scheme 100: Synthesis of tropolone analogue 559.
Scheme 101: Synthesis of tropolones 561 and 562.
Figure 35: o/p-Tropoquinone rings (563 and 564) and benzotropoquinones (565–567).
Scheme 102: Synthesis of benzotropoquinone 566.
Scheme 103: Synthesis of benzotropoquinone 567 via a Diels–Alder reaction.
Figure 36: Products 575–577 through 1,2,3-benzotropoquinone hydrate 569.
Scheme 104: Structures 578–582 prepared from tropoquinone 567.
Figure 37: Two possible structures 583 and 584 for dibenzotropoquinone, and precursor compound 585 for 583.
Scheme 105: Synthesis of saddle-shaped ketone 592 using dibenzotropoquinone 584.
An overview of recent advances in duplex DNA recognition by small molecules
- Sayantan Bhaduri,
- Nihar Ranjan and
- Dev P. Arya
Beilstein J. Org. Chem. 2018, 14, 1051–1086, doi:10.3762/bjoc.14.93
- the past few years. Keywords: alkylators; antibiotic; anticancer; antineoplastic; antiproliferative; DNA recognition; groove binders; hairpin polyamides; Hoechst 33258; intercalators; Review 1. Introduction DNA is one of the central components of cellular machinery and storage unit of genetic
- fashion, they further reported a series of novel hybrids by tethering distamycin A with the antineoplastic agent uramustine via a flexible polymethylene chain of variable length (n = 1 to 6) in order to test their DNA binding affinity and cytotoxicity [57]. It has been observed that hybrid conjugates 8, 9
Graphical Abstract
Figure 1: A figure showing the hydrogen bonding patterns observed in (a) duplex (b) triplex and (c) quadruple...
Figure 2: (a) Portions of MATα1–MATα2 are shown contacting the minor groove of the DNA substrate. Key arginin...
Figure 3: Chemical structures of naturally occurring and synthetic hybrid minor groove binders.
Figure 4: Synthetic structural analogs of distamycin A by replacing one or more pyrrole rings with other hete...
Figure 5: Pictorial representation of the binding model of pyrrole–imidazole (Py/Im) polyamides based on the ...
Figure 6: Chemical structures of synthetic “hairpin” pyrrole–imidazole (Py/Im) conjugates.
Figure 7: (a) Minor groove complex formation between DNA duplex and 8-ring cyclic Py/Im polyamide (conjugate ...
Figure 8: Telomere-targeting tandem hairpin Py/Im polyamides 23 and 24 capable of recognizing >10 base pairs; ...
Figure 9: Representative examples of recently developed DNA minor groove binders.
Figure 10: Chemical structures of bisbenzamidazoles Hoechst 33258 and 33342 and their synthetic structural ana...
Figure 11: Chemical structures of bisamidines such as diminazene, DAPI, pentamidine and their synthetic struct...
Figure 12: Representative examples of recently developed bisamidine derivatives.
Figure 13: Chemical structures of chromomycin, mithramycin and their synthetic structural analogs 91 and 92.
Figure 14: Chemical structures of well-known naturally occurring DNA binding intercalators.
Figure 15: Naturally occurring indolocarbazole rebeccamycin and its synthetic analogs.
Figure 16: Representative examples of naturally occurring and synthetic derivatives of DNA intercalating agent...
Figure 17: Several recent synthetic varieties of DNA intercalators.
Figure 18: Aminoglycoside (neomycin)–Hoechst 33258/intercalator conjugates.
Figure 19: Chemical structures of triazole linked neomycin dimers and neomycin–bisbenzimidazole conjugates.
Figure 20: Representative examples of naturally occurring and synthetic analogs of DNA binding alkylating agen...
Figure 21: Chemical structures of naturally occurring and synthetic analogs of pyrrolobenzodiazepines.
Superstructures with cyclodextrins: Chemistry and applications IV
- Gerhard Wenz
Beilstein J. Org. Chem. 2017, 13, 2157–2159, doi:10.3762/bjoc.13.215
- nanoparticles with the sensitizer Zn-phthalocyanine and the antineoplastic drug docetaxel. These materials might be applicable for dual cancer therapy [15]. Another self-assembled CD nanocarrier for the photoreactive dye squaraine that is useful for photodynamic therapy is described in this Thematic Series [16
Strategies in megasynthase engineering – fatty acid synthases (FAS) as model proteins
- Manuel Fischer and
- Martin Grininger
Beilstein J. Org. Chem. 2017, 13, 1204–1211, doi:10.3762/bjoc.13.119
- antineoplastic doxorubicin and by the antiparasitic avermectin (Figure 1a) [1]. PK are assembled from acyl-coenzyme A (acyl-CoA) units via a series of Claisen-type condensation reactions catalyzed by polyketide synthases (PKS) (Figure 1b). PKS occur as large multifunctional enzymes, termed megasynthases, which
Graphical Abstract
Figure 1: Megasynthases – chemistry and modes of action. a) Products of PKS and FAS megasynthases. b) Reactio...
Figure 2: Compartmentalization of synthesis. a) Surface depiction of fungal FAS (PDB-code: 3hmj) with the upp...
Figure 3: Strategies of megasynthase engineering. a) Mix-and-match approach: A hypothetical chimeric PKS is a...
Figure 4: Preserve-and-adapt approach with FAS. C. ammoniagenes FAS has been engineered in two cooperatively ...
Isoxazole derivatives as new nitric oxide elicitors in plants
- Anca Oancea,
- Emilian Georgescu,
- Florentina Georgescu,
- Alina Nicolescu,
- Elena Iulia Oprita,
- Catalina Tudora,
- Lucian Vladulescu,
- Marius-Constantin Vladulescu,
- Florin Oancea and
- Calin Deleanu
Beilstein J. Org. Chem. 2017, 13, 659–664, doi:10.3762/bjoc.13.65
- ]. The thiophene is a core system of a large number of bioactive molecules such as antineoplastic agents [49], non-steroidal anti-inflammatory drugs [50] or compounds with antibacterial activities against several Gram-positive strains [51]. Thus, 3,5-disubstituted isoxazole derivatives were obtained by
Graphical Abstract
Scheme 1: Synthetic route to 3,5-disubstituted isoxazoles.
N-Propargylamines: versatile building blocks in the construction of thiazole cores
- S. Arshadi,
- E. Vessally,
- L. Edjlali,
- R. Hosseinzadeh-Khanmiri and
- E. Ghorbani-Kalhor
Beilstein J. Org. Chem. 2017, 13, 625–638, doi:10.3762/bjoc.13.61
- prevent gout flare-ups [5][6][7]. Ritonavir (norvir), is an HIV protease inhibitor. It works by blocking the growth of HIV [8][9]. Tiazofurin is a C-nucleoside analogue with antineoplastic activity and acts by inhibition of the guanosine triphosphate (GTP) biosynthesis through a reduction of PI and PIP
Graphical Abstract
Figure 1: Selected examples of bioactive thiazole derivatives.
Figure 2: Some natural sources of thiazoles.
Figure 3: Some important thiazole-based compounds derived from N-propargylamines.
Scheme 1: The synthesis of thiazole-2-thiones 3 through the thermal cyclocondensation of N-propargylamines 1 ...
Scheme 2: (a) One-pot synthesis of 2-benzylthiazolo[3,2-a]benzimidazoles 6 through a base-catalyzed cascade r...
Scheme 3: (a) Synthesis of 2-iminothiazolidines 11 from N-propargylamines 9 and isothiocyanates 10. (b) Synth...
Scheme 4: (a) Synthesis of 2-aminothiazoles 17 through the reaction of ethyl 4-aminobut-2-ynoate salts 15 wit...
Scheme 5: Synthesis of 5-(iodomethylene)-3-methylthiazolidines 27 described by Zhou.
Scheme 6: Mechanism that accounts for the formation of 27.
Scheme 7: Clausen’s synthesis of fluorescein thiazolidines 30.
Scheme 8: Synthesis of multiply substituted thiazolidines 33 from N-propargylamines 32 and blocked N-isothioc...
Scheme 9: (a) Microwave-assisted cyclization of N-propargyl thiocarbamate 34. (b) Synthesis of thiazoles 39 t...
Scheme 10: Synthesis of thiazolidines 42 (42’) from the reaction of β-oxodithioesters 40 (40’) with N-propargy...
Scheme 11: Synthesis of 5-(dibromomethyl)thiazoles 44 via halocyclization of N-propargylamines 43 described by...
Scheme 12: Synthesis of dihydrothiazoles 46 through the treatment of N-propargylamides 45 with Lawesson’s reag...
Scheme 13: Synthesis of thiazoles 49 by treatment of silyl-protected N-propargylamines 47 with benzotriazolylt...
Scheme 14: Mechanism proposed to explain the synthesis of 2,5-disubstituted thiazoles 49 developed by Sasmal.
Scheme 15: Mo-catalyzed cyclization of N-propargylthiocarbamate 50.
Scheme 16: (a) DABCO-mediated intramolecular cyclization of N-(propargylcarbamothioyl)amides 53 to the corresp...
Scheme 17: Proposed mechanism for the generation of the iodine-substituted 4H-1,3-thiazines 56 and 4,5-dihydro...
Scheme 18: Au(III)-catalyzed synthesis of 5-alkylidenedihydrothiazoles 58 developed by Stevens.
Unconventional application of the Mitsunobu reaction: Selective flavonolignan dehydration yielding hydnocarpins
- Guozheng Huang,
- Simon Schramm,
- Jörg Heilmann,
- David Biedermann,
- Vladimír Křen and
- Michael Decker
Beilstein J. Org. Chem. 2016, 12, 662–669, doi:10.3762/bjoc.12.66
- -methoxyhydnocarpin has been described to enhance the antimicrobial activity of berberine [19]. In the light of steadily growing antibiotic resistance any potent and nontoxic MDR inhibitor is of utmost importance. Hydnocarpin has also antineoplastic activity due to sensitizing multidrug-resistant cancer cell lines
Graphical Abstract
Figure 1: Structures of silibinin, isosilybin, and silychristin, and hydnocarpin-type flavonolignans.
Figure 2: Synthetic strategy of semi-synthesis of hydnocarpins from silybins [22].
Scheme 1: Synthesis of ester derivatives of silibinin and conversion to hydnocarpin-type compounds. Reaction ...
Figure 3: Putative mechanism of dehydration of flavanonols under Mitsunobu conditions.
Scheme 2: Attempt to dehydrate catechin. Reagents and conditions: a) p-nitrobenzoic acid, Ph3P, DIAD, THF, rt...
Scheme 3: Preparation of hydnocarpin (4) and isohydnocarpin (6) and attempt to dehydrate silydianin A (11). R...
Synthesis of cyclic N1-pentylinosine phosphate, a new structurally reduced cADPR analogue with calcium-mobilizing activity on PC12 cells
- Ahmed Mahal,
- Stefano D’Errico,
- Nicola Borbone,
- Brunella Pinto,
- Agnese Secondo,
- Valeria Costantino,
- Valentina Tedeschi,
- Giorgia Oliviero,
- Vincenzo Piccialli and
- Gennaro Piccialli
Beilstein J. Org. Chem. 2015, 11, 2689–2695, doi:10.3762/bjoc.11.289
- synthetic building blocks towards the synthesis of biologically relevant compounds such as antiviral and antineoplastic drugs [3][4][5][6][7][8], antibiotics and antifungal agents [9][10][11]. Furthermore, several NNs act as potent second messengers involved in the regulation of key metabolic pathways [12
Graphical Abstract
Figure 1: Structures of cADPR (1), cIDPR (2), cpIDP (3) and cpIMP (4).
Figure 2: Synthetic strategies explored in the cyclization step via phosphodiester bond formation.
Scheme 1: i) (iPr)2NP(OCE)Cl, DIPEA, THF, 1 h, rt; ii) 1) 1H-tetrazole, THF, 2) t-BuOOH, 2 h, rt; iii) 1) (iP...
Scheme 2: i) DNCB, K2CO3, DMF, 4 h, 80 °C; ii) 5-aminopentan-1-ol, DMF, 16 h, 50 °C; iii) Ac2O, pyridine, 2 h...
Figure 3: Effect of 3 and 4 on intracellular [Ca2+] in NGF-differentiated PC12 cells. (A) and (B): representa...
Versatile synthesis and biological evaluation of novel 3’-fluorinated purine nucleosides
- Hang Ren,
- Haoyun An,
- Paul J. Hatala,
- William C. Stevens Jr,
- Jingchao Tao and
- Baicheng He
Beilstein J. Org. Chem. 2015, 11, 2509–2520, doi:10.3762/bjoc.11.272
- ’-fluoro-adenosine 1 in 93% yield. We targeted 9-(3-deoxy-3-fluoro-β-D-ribofuranosyl)purine (1) in particular because it is the 3’-fluorine analogue of nebularine, a naturally occurring antibacterial and antineoplastic agent [42][43]. 3’-Fluoro-6-methylpurine riboside 4, a 6-β-D-MPR mimic 6-Methylpurine-β
- -chloro-intermediates 26 and 48, followed by deprotection, resulted in 6-deaminopurine nucleosides 1 and 21, new analogues of the naturally isolated antibacterial and antineoplastic agent 6-deaminoadenosine, nebularine. Newly synthesized compounds were evaluated for their antitumor activity. Eleven
Graphical Abstract
Figure 1: 6-Subsituted purine 3’-deoxy-3’-fluororibosides 1–15.
Figure 2: 2-Chloro- and 2-aminopurine 3’-deoxy-3’-fluororibosides 16–23.
Figure 3: 3’-Deoxy-3’-fluororibosides constructed from universal intermediate 25.
Scheme 1: Synthesis of 3’-deoxy-3’-fluoropurine ribosides 1–3.
Scheme 2: Synthesis of 6-methylpurine 3’-deoxy-3’-fluororiboside 4.
Scheme 3: Synthesis of 6-substituted purine 3’-deoxy-3’-fluororibosides 5–15.
Scheme 4: Synthesis of 6-substituted 2-chloropurine 3’-deoxy-3’-fluororibosides 16–20.
Scheme 5: Synthesis of 2-aminopurine 3’-deoxy-3’-fluororibosides 21–23.
Dicarboxylic esters: Useful tools for the biocatalyzed synthesis of hybrid compounds and polymers
- Ivan Bassanini,
- Karl Hult and
- Sergio Riva
Beilstein J. Org. Chem. 2015, 11, 1583–1595, doi:10.3762/bjoc.11.174
- in the esterification of the antineoplastic antibiotics mithramycin (5) catalyzed by Candida antarctica lipase A (CAL-A) and chromomycin A3 (6) catalyzed by Candida antarctica lipase B (CAL-B) [24]. In another report a series of mono-substituted troxerutin esters (7a) were synthesized by action of
Graphical Abstract
Scheme 1: Activated derivatives of dicarboxylic acids.
Figure 1: Example of natural compounds selectively acylated with dicarboxylic esters.
Figure 2: C6-dicarboxylic acid diesters derivatives of NAG-thiazoline.
Figure 3: Sylibin dimers obtained by CAL-B catalyzed trans-acylation reactions.
Scheme 2: Biocatalyzed synthesis of paclitaxel derivatives.
Figure 4: 5-Fluorouridine derivatives obtained by CAL-B catalysis.
Scheme 3: Biocatalyzed synthesis of hybrid diesters 17 and 18.
Scheme 4: Hybrid derivatives of sylibin.
Figure 5: Bolaamphiphilic molecules containing (L)- and/or (D)-isoascorbic acid moieties.
Figure 6: Doxorubicin (29) trapped in a polyester made of glycolate, sebacate and 1,4-butandiol units.
Figure 7: Polyesters containing functionalized pentofuranose derivatives.
Figure 8: Polyesters containing disulfide moieties.
Figure 9: Polyesters containing epoxy moieties.
Figure 10: Biocatalyzed synthesis of polyesters containing glycerol.
Figure 11: Iataconic (34) and malic (35) acid.
Figure 12: Oxidized poly(hexanediol-2-mercaptosuccinate) polymer.
Figure 13: C-5-substituted isophthalates.
Figure 14: Curcumin-based polyesters.
Figure 15: Silylated polyesters.
Figure 16: Polyesters containing reactive ether moieties.
Figure 17: Polyesters obtained by CAL-B-catalyzed condensation of dicarboxylic esters and N-substituted dietha...
Figure 18: Polyesters comprising mexiletine (38) moieties.
Figure 19: Poly(amide-co-ester)s comprising a terminal hydroxy moiety.
Figure 20: Polymer comprising α-oxydiacid moieties.
Figure 21: Telechelics with methacrylate ends.
Figure 22: Telechelics with allyl-ether ends.
Figure 23: Telechelics with ends functionalized as epoxides.
DBU-promoted carboxylative cyclization of o-hydroxy- and o-acetamidoacetophenone
- Wen-Zhen Zhang,
- Si Liu and
- Xiao-Bing Lu
Beilstein J. Org. Chem. 2015, 11, 906–912, doi:10.3762/bjoc.11.102
- [4]. Roquinimex was reported as an antineoplastic agent [5]. Traditional methods for accessing these compounds rely heavily on cyclization reactions using diethyl carbonate in the presence of inorganic bases [6][7] or Friedel–Crafts reactions using strong and corrosive acids [8]. In terms of
Graphical Abstract
Figure 1: Selected examples for biologically active 4-hydroxy-2H-chromen-2-one and 4-hydroxy-2(1H)-quinolinon...
Scheme 1: Possible mechanism for the carboxylative cyclization of o-acetamidoacetophenone.
Scheme 2: Cross carboxylative cyclization reaction.
Olefin cross metathesis based de novo synthesis of a partially protected L-amicetose and a fully protected L-cinerulose derivative
- Bernd Schmidt and
- Sylvia Hauke
Beilstein J. Org. Chem. 2014, 10, 1023–1031, doi:10.3762/bjoc.10.102
- antibiotic is aclacinomycin A, which has been used clinically under the name aclarubicin. It is an anthracycline [10] bearing a trisaccharide side chain consisting of L-rhodosamin, 2,6-didesoxy-L-lyxose, and L-cinerulose attached to the aglycon aclavinon [11][12]. It was found to be a potent antineoplastic
- apparently identical catalysts which are often designated just as “10 wt % Pd on carbon” may vary dramatically. Structures of kigamicin B and aclacinomycin A as representative examples for antineoplastic glycoconjugates. RCM-isomerization approach to L-amicetal 4 and alternative CM approaches to L-amicetose
Graphical Abstract
Figure 1: Structures of kigamicin B and aclacinomycin A as representative examples for antineoplastic glycoco...
Scheme 1: RCM-isomerization approach to L-amicetal 4 and alternative CM approaches to L-amicetose.
Scheme 2: Two step desilylation–acetal hydrolysis.
Scheme 3: Deprotection of 11 and 12 to L-amicetose derivative 16.
Scheme 4: Synthesis of a cinerulose-TBS ether 22.
Scheme 5: Deprotection of 24.
An overview of the synthetic routes to the best selling drugs containing 6-membered heterocycles
- Marcus Baumann and
- Ian R. Baxendale
Beilstein J. Org. Chem. 2013, 9, 2265–2319, doi:10.3762/bjoc.9.265
Graphical Abstract
Scheme 1: Scaled industrial processes for the synthesis of simple pyridines.
Scheme 2: Synthesis of nicotinic acid from 2-methyl-5-ethylpyridine (1.11).
Scheme 3: Synthesis of 3-picoline and nicotinic acid.
Scheme 4: Synthesis of 3-picoline from 2-methylglutarodinitrile 1.19.
Scheme 5: Picoline-based synthesis of clarinex (no yields reported).
Scheme 6: Mode of action of proton-pump inhibitors and structures of the API’s.
Scheme 7: Hantzsch-like route towards the pyridine rings in common proton pump inhibitors.
Figure 1: Structures of rosiglitazone (1.40) and pioglitazone (1.41).
Scheme 8: Synthesis of rosiglitazone.
Scheme 9: Syntheses of 2-pyridones.
Scheme 10: Synthesis and mechanism of 2-pyrone from malic acid.
Scheme 11: Polymer-assisted synthesis of rosiglitazone.
Scheme 12: Synthesis of pioglitazone.
Scheme 13: Meerwein arylation reaction towards pioglitazone.
Scheme 14: Route towards pioglitazone utilising tyrosine.
Scheme 15: Route towards pioglitazone via Darzens ester formation.
Scheme 16: Syntheses of the thiazolidinedione moiety.
Scheme 17: Synthesis of etoricoxib utilising Negishi and Stille cross-coupling reactions.
Scheme 18: Synthesis of etoricoxib via vinamidinium condensation.
Figure 2: Structures of nalidixic acid, levofloxacin and moxifloxacin.
Scheme 19: Synthesis of moxifloxacin.
Scheme 20: Synthesis of (S,S)-2,8-diazabicyclo[4.3.0]nonane 1.105.
Scheme 21: Synthesis of levofloxacin.
Scheme 22: Alternative approach to the levofloxacin core 1.125.
Figure 3: Structures of nifedipine, amlodipine and clevidipine.
Scheme 23: Mg3N2-mediated synthesis of nifedipine.
Scheme 24: Synthesis of rac-amlodipine as besylate salt.
Scheme 25: Aza Diels–Alder approach towards amlodipine.
Scheme 26: Routes towards clevidipine.
Figure 4: Examples of piperidine containing drugs.
Figure 5: Discovery of tiagabine based on early leads.
Scheme 27: Synthetic sequences to tiagabine.
Figure 6: Structures of solifenacin (2.57) and muscarine (2.58).
Scheme 28: Enantioselective synthesis of solifenacin.
Figure 7: Structures of DPP-4 inhibitors of the gliptin-type.
Scheme 29: Formation of inactive diketopiperazines from cis-rotameric precursors.
Figure 8: Co-crystal structure of carmegliptin bound in the human DPP-4 active site (PDB 3kwf).
Scheme 30: Improved route to carmegliptin.
Figure 9: Structures of lamivudine and zidovudine.
Scheme 31: Typical routes accessing uracil, thymine and cytosine.
Scheme 32: Coupling between pyrimidones and riboses via the Vorbrüggen nucleosidation.
Scheme 33: Synthesis of lamivudine.
Scheme 34: Synthesis of raltegravir.
Scheme 35: Mechanistic studies on the formation of 3.22.
Figure 10: Structures of selected pyrimidine containing drugs.
Scheme 36: General preparation of pyrimidines and dihydropyrimidones.
Scheme 37: Synthesis of imatinib.
Scheme 38: Flow synthesis of imatinib.
Scheme 39: Syntheses of erlotinib.
Scheme 40: Synthesis of erlotinib proceeding via Dimroth rearrangement.
Scheme 41: Synthesis of lapatinib.
Scheme 42: Synthesis of rosuvastatin.
Scheme 43: Alternative preparation of the key aldehyde towards rosuvastatin.
Figure 11: Structure comparison between nicotinic acetylcholine receptor agonists.
Scheme 44: Syntheses of varenicline and its key building block 4.5.
Scheme 45: Synthetic access to eszopiclone and brimonidine via quinoxaline intermediates.
Figure 12: Bortezomib bound in an active site of the yeast 20S proteasome ([114], pdb 2F16).
Scheme 46: Asymmetric synthesis of bortezomib.
Figure 13: Structures of some prominent piperazine containing drugs.
Figure 14: Structural comparison between the core of aplaviroc (4.35) and a type-1 β-turn (4.36).
Scheme 47: Examplary synthesis of an aplaviroc analogue via the Ugi-MCR.
Scheme 48: Syntheses of azelastine (5.1).
Figure 15: Structures of captopril, enalapril and cilazapril.
Scheme 49: Synthesis of cilazapril.
Figure 16: Structures of lamotrigine, ceftriaxone and azapropazone.
Scheme 50: Synthesis of lamotrigine.
Scheme 51: Alternative synthesis of lamotrigine (no yields reported).
Figure 17: Structural comparison between imiquimod and the related adenosine nucleoside.
Scheme 52: Conventional synthesis of imiquimod (no yields reported).
Scheme 53: Synthesis of imiquimod.
Scheme 54: Synthesis of imiquimod via tetrazole formation (not all yields reported).
Figure 18: Structures of various anti HIV-medications.
Scheme 55: Synthesis of abacavir.
Figure 19: Structures of diazepam compared to modern replacements.
Scheme 56: Synthesis of ocinaplon.
Scheme 57: Access to zaleplon and indiplon.
Scheme 58: Different routes towards the required N-methylpyrazole 6.65 of sildenafil.
Scheme 59: Polymer-supported reagents in the synthesis of key aminopyrazole 6.72.
Scheme 60: Early synthetic route to sildenafil.
Scheme 61: Convergent preparations of sildenafil.
Figure 20: Comparison of the structures of sildenafil, tadalafil and vardenafil.
Scheme 62: Short route to imidazotriazinones.
Scheme 63: Alternative route towards vardenafils core imidazotriazinone (6.95).
Scheme 64: Bayer’s approach to the vardenafil core.
Scheme 65: Large scale synthesis of vardenafil.
Scheme 66: Mode of action of temozolomide (6.105) as methylating agent.
Scheme 67: Different routes to temozolomide.
Scheme 68: Safer route towards temozolomide.
Figure 21: Some unreported heterocyclic scaffolds in top market drugs.
Engineering of indole-based tethered biheterocyclic alkaloid meridianin into β-carboline-derived tetracyclic polyheterocycles via amino functionalization/6-endo cationic π-cyclization
- Piyush K. Agarwal,
- Meena D. Dathi,
- Mohammad Saifuddin and
- Bijoy Kundu
Beilstein J. Org. Chem. 2012, 8, 1901–1908, doi:10.3762/bjoc.8.220
- in the literature. β-Carbolines are some of the most widely distributed alkaloids, associated with activities ranging from antineoplastic (tubulin binding) [44][45][46], anticonvulsive, hypnotic and anxiolytic (benzodiazepine receptor ligands) [47], antimicrobial as well as topoisomerase-II
Graphical Abstract
Figure 1: Structure of meridianins A–G.
Scheme 1: Synthesis of functionalized meridianin with an amino group at position 5.
Scheme 2: Synthesis of a functionalized meridianin with an amino group at position 5.
Scheme 3: Synthesis of substrate for the modified Pictet–Spengler reaction.
Scheme 4: The Pictet–Spengler reaction involving substrate 2a. Reagents and conditions: (i) RCHO, 2% triflic ...
Scheme 5: Synthesis of dihydropyrimido-β-carbolines: (i) R-CHO, 2% triflic acid in DMF, 120 °C, 16 h.
Scheme 6: Synthesis of substrates 18a–c for the modified Pictet–Spengler reaction.
Scheme 7: General strategy for the Pictet–Spengler reaction involving substrates 18. Reagents and conditions:...
Directed aromatic functionalization in natural-product synthesis: Fredericamycin A, nothapodytine B, and topopyrones B and D
- Charles Dylan Turner and
- Marco A. Ciufolini
Beilstein J. Org. Chem. 2011, 7, 1475–1485, doi:10.3762/bjoc.7.171
- properties of topopyrones are sufficiently interesting that a number of groups embarked on a total synthesis [94][95][96]. Our own involvement in this area was motivated by an interest in topoisomerase-I inhibitors, which are important antineoplastic resources [97], the archetype of which is camptothecin [81
Graphical Abstract
Scheme 1: Structure and retrosynthetic analysis of fredericamycin A.
Scheme 2: Assembly of the isoquinolone segment of fredericamycin.
Scheme 3: Synthesis of a naphthalide precursor to the quinoid moiety of fredericamycin.
Scheme 4: Palladium-mediated cyclization of a fredericamycin model system.
Scheme 5: Synthesis of the precursor of fredericamycin and the facile air oxidation thereof.
Scheme 6: Formal synthesis of fredericamycin A.
Figure 1: Structure of nothapodytine B.
Scheme 7: A useful pyridone synthesis.
Scheme 8: Retrosynthetic logic for nothapodytine B.
Scheme 9: Preparation of a key nothapodytine fragment.
Scheme 10: Total synthesis of nothapodytine B.
Figure 2: Structures of topopyrones.
Scheme 11: Retrosynthetic logic for the linear series of topopyrones.
Scheme 12: Construction of the molecular subunit common to all topopyrones.
Scheme 13: Difficulties encountered during the merger of the topopyrone D moieties.
Scheme 14: Efficient synthesis of a simplified anthraquinone.
Scheme 15: Total synthesis of topopyrone D.
Scheme 16: Total synthesis of topopyrone B.
Synthesis of some novel hydrazono acyclic nucleoside analogues
- Mohammad N. Soltani Rad,
- Ali Khalafi-Nezhad and
- Somayeh Behrouz
Beilstein J. Org. Chem. 2010, 6, No. 49, doi:10.3762/bjoc.6.49
- antineoplastic (e.g. bisantrene [4][10]), contain a hydrazone moiety in their structure. Furthermore, various structurally related miconazole bioactive hydrazones are known as antimicrobial and antifungal agents [11][12]. The significance of nucleoside chemistry in drug discovery is well-known and fully
Graphical Abstract
Figure 1: Chemical structures of miconazole (A), oxiconazole (B) and hydrazono acyclic nucleoside analogue (C...
Scheme 1: Synthetic pathway for hydrazono acyclic nucleoside 2a–2g.
Scheme 2: Synthetic pathway for hydrazono acyclic nucleoside 2h–2o.
